Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 604.25M
June 30, 2026 644.16M
March 31, 2026 688.43M
December 31, 2025 739.83M
September 30, 2025 573.39M
June 30, 2025 614.16M
March 31, 2025 660.36M
December 31, 2024 443.59M
September 30, 2024 467.96M
June 30, 2024 488.83M
March 31, 2024 338.07M
December 31, 2023 345.12M
September 30, 2023 358.97M
Date Value
June 30, 2023 371.22M
March 31, 2023 232.86M
December 31, 2022 176.60M
September 30, 2022 104.57M
June 30, 2022 106.90M
March 31, 2022 111.61M
December 31, 2021 77.65M
September 30, 2021 140.86M
June 30, 2021 157.68M
March 31, 2021 171.16M
December 31, 2020 -21.86M
September 30, 2020 117.58M
June 30, 2020 0.0235M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Agenus, Inc. -105.37M
Amgen, Inc. 14.35B
Anika Therapeutics, Inc. 137.58M
BioCryst Pharmaceuticals, Inc. -397.38M
Imunon, Inc. 2.622M

Shareholders Equity (Quarterly) Related Metrics